濮阳东方医院妇科收费非常低濮阳东方男科医院收费不高,濮阳东方妇科很正规,濮阳东方医院男科治阳痿很不错,濮阳东方男科技术值得信任,濮阳东方医院看妇科病技术很权威,濮阳东方医院妇科技术好,濮阳东方医院妇科口碑评价很好

BEIJING, April 19 (Xinhuanet) -- The case in the Hollywood blockbuster "The Social Network" continues in real life.Twins Cameron and Tyler Winklevoss on Monday filed another appeal against their Harvard classmate and Facebook founder Mark Zuckerberg.The Winklevosses claim that the case needs to be reviewed by a special 11-judge panel in the latest appeal, after a three-judge panel of the 9th U.S. Circuit Court of Appeals ruled against the brothers last week.The twins initially claimed that Zuckerberg had stolen their idea for the website but agreed to drop their lawsuit in 2008 in exchange for 20 million dollars in cash and stock in the company.But later they discovered the stock was worth less than claimed at the time and sought to have the deal voided, the brothers said.

LOS ANGELES, March 18 (Xinhua) -- The moon will move closer to Earth than it has been in more than 18 years Saturday night, space. com reported on Friday.On Saturday afternoon at 3 p.m. Eastern Daylight Time (1900 MGT) , the "supermoon", as dubbed by some observers, will arrive at its closest point to the Earth in 2011: a distance of 221,565 miles ( 356,575 kilometers) away, and only 50 minutes earlier, the moon will officially be full, the report said.At its peak, the supermoon may appear 14 percent larger and 30 percent brighter than lesser full moons (when the moon is at its farthest from Earth), weather permitting, said the report.Yet to the casual observer, it may be hard to tell the difference, according to the report.Scientists say it is a fluke of orbital mechanics that brings the moon closer to Earth.The supermoon will not cause natural disasters, such as the Japan earthquake, NASA scientists say.In December 2008, there was a near-supermoon when the moon turned full four hours away from its perigee - the point in its orbit that is closest to Earth. But this month, the full moon and perigee are just under one hour apart, promising spectacular views, depending on local conditions, the report said.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

BEIJING, May 24 (Xinhuanet) -- Scientists revealed for the first time the molecular structure of proteins, which enables bacteria to transfer electrical charges, according to a new study. The revelation was published in Proceedings of the National Academy of Sciences in the U.S. on Monday.Scientists used a technique called "x-ray crystallography" to reveal the molecular structure of proteins, which work as atom-sized "wires" discharging excess electricity."This is an exciting advance in our understanding of how some bacterial species move electrons from the inside to the outside of a cell," said lead author Tom Clarke of the University of East Anglia's School of Biological Sciences in Norwich, England.He said this discovery means "We can now start developing efficient 'bio-batteries' as the viable energy source in the future."Still, it could take perhaps a decade to go. Before that, existing uses of such bacteria needed to become 100 or 1,000 times more efficient, he said.The advance could also hasten the development of microbe technology that can help clean up oil or uranium pollution, he said.Microbes might in future be enlisted to clean up nuclear accidents such as Japan's Fukushima Daiichi disaster, he added.

SAN FRANCISCO, April 5 (Xinhua) -- Apple Inc.'s iPad 2 has topped the ratings by Consumer Reports, an influential U.S. magazine for product reviews, in the latest tests of the 10 most- promising tablet computers.According to the ratings released on Tuesday, the Apple iPad 2 with Wi-Fi plus 3G (32G), which is priced at 730 U.S. dollars, topped the ratings, scoring "excellent" in nearly every category.Besides several models from Apple, other brands tested include Archos, Dell, Motorola, Samsung and Viewsonic. Each tablet was evaluated on 17 criteria, including touch-screen responsiveness, versatility, portability, screen glare and ease of use."So far, Apple is leading the tablet market in both quality and price, which is unusual for a company whose products are usually premium priced," Paul Reynolds, electronics editor at Consumer Reports, said in a statement.The Motorola Xoom, whose price is 800 dollars, stood out as the iPad 2's main rival. It boasts several features that the iPad lacks, including a built-in memory card reader and support for the Flash videos.The first-generation iPad, priced at 580 dollars, also outscored many of the other models tested but tied with the Motorola Xoom, according to tests by Consumer Reports.